Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
He raised approximately $850,000 by February, enough money to fund the somatostatin research projects. By August 1977, the research teams managed to create the first bacterium capable of synthesizing somatostatin. This was the proof of concept that the fledgling company sought. On December 2, 1977, Swanson and the scientists held a press conference announcing their findings. Following their success with the proof of concept, Swanson then directed the scientists to pursue the creation of a bacterium that synthesized human insulin. Two other scientific teams were already attempting to carry out such a project, but Swanson moved quickly to ensure that they synthesized it first. By early 1978, his priorities were to obtain a lab space for the scientists, corporate contracts, and more funding for Genentech. In order to attract the best scientists, Swanson, with the assistance of Boyer, tried to create an attractive environment for academic scientists. It was because of this that scientists at Genentech were allowed to publish their findings in scientific journals. The restriction was that they could publish only after the appropriate patents had already been filed. By February 1978, Swanson leased a 10,000-square-foot section of an airfreight warehouse, which would serve as Genentech's first lab space. Later that year, Swanson also secured a partnership with Eli Lilly; Genentech would receive $50,000 a month to pursue the human insulin project.
Target validation (TV) → Assay development → High-throughput screening (HTS) → Hit to lead (H2L) → Lead optimization (LO) → Preclinical development → Clinical development The hit to lead stage starts with confirmation and evaluation of the initial screening hits and is followed by synthesis of analogs (hit expansion). Typically the initial screening hits display binding affinities for their biological target in the micromolar (10−6 molar concentration) range. Through limited H2L optimization, the affinities of the hits are often improved by several orders of magnitude to the nanomolar (10−9 M) range. The hits also undergo limited optimization to improve metabolic half life so that the compounds can be tested in animal models of disease and also to improve selectivity against other biological targets binding that may result in undesirable side effects. On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.
VCl3 + 4 Na + 6 CO + 2 diglyme → Na(diglyme)2[V(CO)6] + 3 NaCl [V(CO)6]− + H+ → H[V(CO)6] → 1/2 H2 + V(CO)6 In the aqueous phase, nickel or cobalt salts can be reduced, for example by sodium dithionite. In the presence of carbon monoxide, cobalt salts are quantitatively converted to the tetracarbonylcobalt(−1) anion:
An analogue, asarone, is more potent than myristicin, elemicin, or safrole in producing hypnotic-like effects in rodents. Asarone is a natural precursor to the psychedelic amphetamine TMA-2, which is substantially more potent as a psychedelic drug than analogues like TMA and mescaline. Asarone is present in Acorus calamus and this root has limited reports of producing stimulant- and psychedelic- or LSD-like effects in humans. However, Shulgin reported that pure asarone produced no effects whatsoever at doses of up to 70 mg orally. For comparison, TMA-2 produces threshold effects at a dose of 10 mg orally and its typical or effective dose range is 20 to 40 mg orally. In accordance with Shulgin's findings, no psychoactive effects were reported and TMA-2 was not detected in a clinical series of Acorus calamus poisonings.
{\displaystyle Q=\left[m_{\text{N}}\left({\ce {^{\mathit {A}}_{\mathit {Z}}X}}\right)-m_{\text{N}}\left({\ce {^{\mathit {A}}_{{\mathit {Z}}+1}X'}}\right)-m_{\text{e}}-m_{{\overline {\nu }}_{\text{e}}}\right]c^{2}}
Sources: en.wikipedia.org
== Breast == Breast cancer Ductal carcinoma in situ Inflammatory breast cancer Invasive ductal carcinoma Invasive lobular carcinoma Tubular carcinoma Invasive cribriform carcinoma of the breast (also termed invasive cribriform carcinoma) Medullary carcinoma Male breast cancer Phyllodes tumor Mammary secretory carcinoma Mucinous carcinoma of the breast Papillary carcinomas of the breast
== Types == Neuromuscular fatigue can be classified as either "central" or "peripheral" depending on its cause. Central muscle fatigue manifests as an overall sense of energy deprivation, while peripheral muscle fatigue manifests as a local, muscle-specific inability to do work.
=== Federal dissolution; the roots of mistrust === Meanwhile, secessionist black Rhodesian parties won electoral victories in Northern Rhodesia and Nyasaland, and Harold Macmillan's Conservative administration in Britain moved towards breaking up the Federation, resolving that it had become untenable. In February 1962, the British Secretary of State for Commonwealth Relations, Duncan Sandys, secretly informed the Nyasaland nationalist leader Hastings Banda that secession would be allowed. A few days later, he horrified Welensky by telling him that "we British have lost the will to govern". "But we haven't", retorted Julian Greenfield, Welensky's Law Minister. Macmillan's Deputy Prime Minister and First Secretary of State, R. A. Butler, who headed British oversight of the Federation, officially announced Nyasaland's right to secede in December 1962. Four months later, he informed the three territories that he was going to convene a conference to decide the Federation's future. As Southern Rhodesia had been the UK's legislative partner in forming the Federation in 1953, it would be impossible (or at least very difficult) for Britain to dissolve the union without Southern Rhodesia's co-operation. Field could therefore potentially hamstring the British by refusing to attend the conference until they pledged to grant his country full independence. According to Field, Smith and other RF politicians, Butler made several such guarantees orally to ensure their co-operation at the conference, but repeatedly refused to give anything on paper.
Because lichens accumulate pollutants over time, they allow for high-density spatial sampling, even in areas lacking automated monitoring stations. This makes X. parietina particularly useful for retrospective pollution assessments and long-term environmental monitoring. Findings from the Adriatic Italy study support its role as a reliable tool for tracking pollution trends, identifying pollutant sources, and informing environmental planning and public health strategies. Environmental influences on growth rate have important implications for biomonitoring studies that use X. parietina to assess air quality. Because the lichen accumulates pollutants over time, differences in growth rates between populations can affect pollutant load measurements. Thalli in humid, cooler environments may accumulate contaminants at a lower rate than those in drier, warmer habitats simply due to differences in growth and dilution effects. Consequently, lichen-based biomonitoring efforts must consider local climatic conditions to ensure accurate comparisons of atmospheric pollution levels across regions.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.